Glycomimetics Inc (GLYC) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Glycomimetics Inc

CIK: 1007019 Ticker: GLYC

Exhibit 99.1

Picture 1





ROCKVILLE, MD, March 1, 2017

–  GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2016. 

“In 2016, GlycoMimetics made significant progress across its clinical pipeline, perhaps most significantly in the maturing data from our study of GMI-1271, an E-selectin antagonist, in acute myeloid leukemia (AML). Starting early in the year, continuing mid-year at the European Hematology Association (EHA), and finally, in December at the 58th Annual American Society of Hematology (ASH) Annual Meeting, we presented results from the Phase 2 portions of this study, in both newly diagnosed and relapsed/refractory patients. The ongoing trial is expected to complete enrollment in the first half of this year. Importantly the data to date suggest a very real potential for bringing a differentiated commercial product to this vastly underserved market.

Beyond this program, we initiated two new trials in 2016, a Phase 1 clinical trial of GMI-1271 in multiple myeloma (MM), and a Phase 1 clinical trial of our next drug candidate GMI-1359, a dual antagonist of both E-selectin and CXCR4, in healthy volunteers.  These accomplishments position us for significant news flow in 2017. In addition, the Phase 3 trial of rivipansel being conducted by Pfizer continues to enroll sickle cell patients with the goal of completion of enrollment in the second half of 2018,” said Rachel King, GlycoMimetics’ Chief Executive Officer.

Key Operational Highlights for the Fourth Quarter of 2016:


At the ASH Annual Meeting in San Diego held in December 2016, GlycoMimetics presented results from its Phase 1/2 clinical trial of GMI-1271, in which high rates of remission and favorable tolerability were observed among AML patients in both arms of the trial. In the Phase 1/2 clinical trial, clinicians are studying the use of GMI-1271 along with chemotherapy. For a total of 33 study participants with relapsed or refractory disease in one arm of the trial, the complete response (CR) rate was 45 percent. For 11 newly diagnosed study participants 60 or more years of age in the

The following information was filed by Glycomimetics Inc (GLYC) on Wednesday, March 1, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Glycomimetics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Glycomimetics Inc.


Assess how Glycomimetics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Glycomimetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (parenthetical)
Statements Of Cash Flows
Statements Of Operations And Comprehensive Loss
Statements Of Stockholders' Equity
Accrued Expenses
Accrued Expenses (tables)
Accrued Expenses - Summary Of Accrued Expenses (detail)
Description Of The Business
Description Of The Business - Additional Information (detail)
Employee Benefit Plan
Employee Benefit Plan (details)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate And Effective Income Tax Rate (detail)
Income Taxes - Schedule Of Gross Deferred Tax Asset And Related Valuation Allowance (detail)
Net (loss) Income Per Share Of Common Stock (detail)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (tables)
Operating Leases
Operating Leases (details)
Operating Leases (tables)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (tables)
Prepaid Expenses And Other Current Assets - Summary Of Prepaid Expenses And Other Current Assets (detail)
Property And Equipment
Property And Equipment (detail)
Property And Equipment (tables)
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited) (detail)
Quarterly Financial Information (unaudited) (tables)
Research And License Agreements
Research And License Agreements - Additional Information (detail)
Stockholders Equity (tables)
Stockholders' Equity
Stockholders' Equity - Common Stock Warrants (detail)
Stockholders' Equity - Company's Stock Option Activity (detail)
Stockholders' Equity - Incentive Plans (detail)
Stockholders' Equity - Preferred And Common Stock (detail)
Stockholders' Equity - Stock-based Compensation Expense (detail)
Stockholders' Equity - Summary Of Rsu Activity (detail)
Stockholders' Equity - Weighted-average Assumptions (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Property And Equipment (detail)

Material Contracts, Statements, Certifications & more

Glycomimetics Inc provided additional information to their SEC Filing as exhibits

Ticker: GLYC
CIK: 1253689
Form Type: 10-K Annual Report
Accession Number: 0001558370-17-001198
Submitted to the SEC: Wed Mar 01 2017 9:31:17 AM EST
Accepted by the SEC: Wed Mar 01 2017
Period: Saturday, December 31, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: